Literature DB >> 11771079

Prevalence of symptomatic BPE among Malaysian men aged 50 and above attending screening during prostate health awareness campaign.

G C Teh1, R M Sahabudin, T C Lim, W L Chong, S Woo, M Mohan, A Khairullah, P Abrams.   

Abstract

OBJECTIVE: To study the prevalence of symptomatic BPE among Malaysian men age 50 and above attending prostate health awareness campaign and to identify differences in prevalence between different ethnic groups residing within metropolitan Kuala Lumpur.
MATERIALS AND METHODS: Demographic data and the completed International Prostate Symptom Score (IPSS), maximal uroflow rate (Qmax) and prostate size of volunteers, aged 50 and above, who attended the prostate health awareness campaign were analyzed. Subjects with known prostate diseases or prostate surgery, bladder disorders and neurological disorders were excluded.
RESULTS: 2086 volunteers attended the campaign. 575 men fulfilled the inclusion criteria and their demographic data, IPSS; peak flow rate and prostate volume were analysed. Overall, 18.9% and 39.6% of the men were severely and moderately symptomatic, respectively. The prevalence of moderate to severe lower urinary tract symptoms (LUTS) in Malays, Chinese and Indians were 70%, 59% and 50% respectively (p = 0.004). The commonest bothersome symptoms were nocturia (56%), frequency (50.4%) and sense of incomplete voiding (43.5%). The mean peak flow rate of the subjects was 15.4 ml/s. 20.9% and 55.2% of the subjects had peak flow less than 10 ml/sec and 15 ml/sec respectively. The mean prostate size was 25.1 cc. There is no significant difference in term of maximal flow rate and prostate size among Malays, Chinese and Indians in Malaysia. A good correlation was found between the total symptom score and the single disease-specific quality of life question (r = 0.69, p < 0.001). The correlation between IPSS and peak flow rate (r = -0.22, p < 0.001) and prostate volume (r = 0.11, p = 0.009) was weak. There was no correlation between IPSS and age (r = 0.06, p = 0.17). The prevalence of symptomatic benign prostate enlargement (BPE) was 39.3%. The prevalence increased 8% per decade from 41.7% for men aged 50 to 59 to 65.4% for men aged 70 or more. There is no significant difference in prevalence of symptomatic BPE among the three ethnic groups. The Prevalence of BPO was 15.8%.
CONCLUSION: The correlation between symptom score, maximal flow rate and prostate size was poor and one cannot predict the value of one parameter by knowing one or more of the other parameters. There is a high prevalence of LUTS suggestive of benign prostatic obstruction in the apparently healthy Malaysian aged 50 and above attending the prostate health awareness campaign.

Entities:  

Mesh:

Year:  2001        PMID: 11771079

Source DB:  PubMed          Journal:  Med J Malaysia        ISSN: 0300-5283


  5 in total

1.  Profile of men's health in Malaysia: problems and challenges.

Authors:  Seng Fah Tong; Wah Yun Low; Chirk Jenn Ng
Journal:  Asian J Androl       Date:  2011-02-28       Impact factor: 3.285

2.  Assessment of lower urinary tract symptoms in Saudi men using the International Prostate Symptoms Score.

Authors:  Mostafa A Arafa; Karim Farhat; Saad Aqdas; Mohamed Al-Atawi; Danny M Rabah
Journal:  Urol Ann       Date:  2015 Apr-Jun

3.  The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis.

Authors:  Shaun Wen Huey Lee; Esther Mei Ching Chan; Yin Key Lai
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

4.  Outcomes of Prostate Artery Embolisation in Patients with Severe Symptoms of Benign Prostate Hyperplasia.

Authors:  Rohana Abdul Rahim; Goh Eng Hong; Nik Azuan Nik Ismail; Rozman Zakaria
Journal:  Malays J Med Sci       Date:  2021-12-22

5.  Lower Urinary Tract Symptoms: Prevalence and Factors Associated with Help-Seeking in Male Primary Care Attendees.

Authors:  Noor Mikraz Mohamad Isa; Aznida Firzah Abdul Aziz
Journal:  Korean J Fam Med       Date:  2020-02-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.